These results confirm that B cells in gliomas can promote immunosuppression with pro-tumorigenic effects but can also exhibit antitumorigenic activity that depends on their immunological subtypes such as CD137+ as well as various co-stimulatory treatment conditions such as an additional blockade of PD-L1 [34,35,36]. Here, CD274 is linked to glioma.